Cellular and Molecular Gastroenterology and Hepatology, published by Elsevier Inc, is a premier Open Access journal dedicated to advancing the understanding and treatment of gastrointestinal and liver diseases. Since its inception in 2015, this journal has established itself as a leading publication within its field, boasting impressive metrics with a 2023 Q1 ranking in both Gastroenterology and Hepatology. It ranks #10 out of 167 in Gastroenterology and #11 out of 82 in Hepatology on Scopus, placing it in the 94th and 87th percentiles, respectively. This journal aims to disseminate high-quality, peer-reviewed research that fosters innovative solutions for clinical challenges, making it an invaluable resource for researchers, healthcare professionals, and students alike. With open access, all published content is readily available to a global audience, ensuring that critical findings in cellular and molecular biology related to gastroenterology and hepatology reach those who can benefit the most from the latest advances in the field. For more information, please visit us at our address in San Diego, CA, or explore our articles online.

Hepatology Forum is an esteemed journal dedicated to disseminating cutting-edge research and insights in the fields of gastroenterology and hepatology. Published by KARE PUBL in Turkey, this journal serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to advance their knowledge and practices related to liver diseases and gastrointestinal disorders. With an ISSN of 1307-5888 and an E-ISSN of 2757-7392, it features peer-reviewed articles that encompass a wide range of topics from basic research to clinical applications. Although categorized in the Q3 quartile for both gastroenterology and hepatology in 2023, Hepatology Forum continues to show significant potential for growth and impact, as evidenced by its Scopus rankings. Through its commitment to open scientific exchange, the journal not only facilitates the sharing of innovative methodologies and findings but also fosters networking among professionals in the field. As it converges through the years from 2020 to 2024, Hepatology Forum remains an important resource for the advancement of liver health and diseases, appealing to both established experts and emerging scholars alike.

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.

JOURNAL OF HEPATOLOGY, published by Elsevier, stands as a preeminent source in the field of Hepatology, with its impact underscored by a remarkable 2023 Category Quartile of Q1 and a Scopus rank of 3rd out of 82 journals, placing it in the 96th percentile for the discipline. Since its inception in 1985, this journal has been a vital conduit for the dissemination of pioneering research, clinical studies, and reviews related to liver diseases and their impact on global health. Although it currently does not offer open access options, the journal is committed to providing top-tier content to its readership—researchers, medical professionals, and students—in order to advance knowledge and foster innovation in hepatology. With a broad and inclusive scope, it aims to cover significant breakthroughs, therapeutic advancements, and epidemiological studies, continually pushing the boundaries of understanding in liver health. The journal is based in Amsterdam, Netherlands, and remains an essential resource for those dedicated to the progression of hepatologic science.

HPB is a premier journal dedicated to advancing the fields of Gastroenterology and Hepatology, published by Elsevier Science Ltd. With an impressive impact factor reflective of its high-quality research output, HPB has earned its place as a Q1 journal in Gastroenterology and Q2 in Hepatology as of 2023. The journal, available in both print and electronic formats (ISSN: 1365-182X; E-ISSN: 1477-2574), serves as a vital platform for multidisciplinary research, encompassing clinical and experimental studies, aimed at improving patient care and outcomes related to liver and biliary diseases. Since its inception in 2000, HPB has published influential articles that have shaped practice and policy in the field. Located in the United Kingdom, at 125 London Wall, London EC2Y 5AS, the journal is poised to continue its mission of fostering innovation and collaboration among researchers, healthcare professionals, and academicians worldwide.

The International Journal of Hepatology, published by HINDAWI LTD, is a premier open-access journal dedicated to the field of hepatology. Since its inception, this journal has championed the dissemination of cutting-edge research and reviews pertaining to liver health, diseases, and therapies. With an ISSN of 2090-3448, the journal has been committed to open-access publishing since 2011, ensuring that vital knowledge is readily available to researchers, clinicians, and students worldwide. Based in Egypt, this journal stands out in its category, achieving a Q3 ranking in 2023 within the scope of Hepatology by Scopus, which ranks it #43 out of 82 in the field. The International Journal of Hepatology offers a platform for significant findings and discussions that influence clinical practices and foster new research directions, thus playing a crucial role in advancing the understanding of liver diseases and their management.

Liver Research, published by KEAI PUBLISHING LTD, is a pioneering open-access journal dedicated to advancing knowledge in the fields of hepatology and gastroenterology since its inception in 2017. With a significant impact factor reflected in its 2023 category quartiles (Q2 in Gastroenterology and Q3 in Hepatology) and Scopus rankings, it stands as an essential platform for researchers, clinicians, and students seeking to stay updated on the latest developments and breakthroughs in liver diseases and treatments. Based in Beijing, China, this journal nurtures collaboration and innovation, ensuring that valuable insights are freely accessible to a global audience. As it continues its coverage until 2024, Liver Research plays a pivotal role in bridging the gap between research and clinical practice, making it a cornerstone resource for those committed to improving liver health.

Egyptian Journal of Dermatology and Venereology is a premier peer-reviewed journal dedicated to advancing the fields of dermatology and venereology. Published by Wolters Kluwer Medknow Publications, this journal provides a vital platform for researchers, clinicians, and healthcare professionals to share cutting-edge research, case studies, and reviews that contribute to the understanding and treatment of skin and sexually transmitted diseases. With an ISSN of 1110-6530 and an E-ISSN of 2314-7407, the journal ensures global accessibility and visibility of its content, fostered by its commitment to high-quality publications. Although it operates with restricted access, the Egyptian Journal of Dermatology and Venereology remains an essential resource for practitioners and academics alike, supporting the dissemination of knowledge and innovation in skin health. Situated in Mumbai, India, the journal reflects a diverse pool of contributions that enrich our understanding of dermatological practices and principles on an international scale.

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.